tetano
Editor, Senior Moderator
New Microbes New Infect. 2020 Apr 20:100682. doi: 10.1016/j.nmni.2020.100682. [Epub ahead of print]
A short review on antibody therapy for COVID-19.
Kumar GV[SUP]1[/SUP], Jeyanthi V[SUP]2[/SUP], Ramakrishnan S[SUP]3[/SUP].
Author information
Abstract
The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.
? 2020 Published by Elsevier Ltd.
KEYWORDS:
Convalescent plasma therapy; Monoclonal antibody therapy; SARS-CoV-2
PMID:32313660PMCID:PMC7167584DOI:10.1016/j.nmni.2020.100682
A short review on antibody therapy for COVID-19.
Kumar GV[SUP]1[/SUP], Jeyanthi V[SUP]2[/SUP], Ramakrishnan S[SUP]3[/SUP].
Author information
Abstract
The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.
? 2020 Published by Elsevier Ltd.
KEYWORDS:
Convalescent plasma therapy; Monoclonal antibody therapy; SARS-CoV-2
PMID:32313660PMCID:PMC7167584DOI:10.1016/j.nmni.2020.100682